Premium
Pharmacokinetics and pharmacodynamics of meloxicam in piglets
Author(s) -
FOSSE T. K.,
HAGA H. A.,
HORMAZABAL V.,
HAUGEJORDEN G.,
HORSBERG T. E.,
RANHEIM B.
Publication year - 2008
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.2008.00958.x
Subject(s) - meloxicam , pharmacodynamics , pharmacokinetics , exudate , chemistry , pharmacology , saline , thromboxane b2 , carrageenan , prostaglandin e2 , prostaglandin , medicine , anesthesia , biochemistry , platelet , pathology
The pharmacokinetics and pharmacodynamics of meloxicam in piglets (16–23 days old) were studied using a stratified parallel group design. One group ( n = 13) received 0.4 mg/kg meloxicam intravenously, while the other group ( n = 12) received physiological saline solution. A carrageenan‐sponge model of acute inflammation was used to evaluate the effects of meloxicam. The plasma clearance was low (0.061 L/kg/h), the volume of distribution was low (0.19 L/kg) and the elimination half‐life was short (2.7 h). At most time points, the mean concentration of meloxicam in plasma exceeded the concentrations in exudate indicating a limited accumulation of the drug at the site of the inflammation. There were significant differences between the groups in the exudate prostaglandin E 2 (PGE 2 ) concentration, but the inhibition of PGE 2 in the meloxicam group was limited. The inhibition of thromboxane B 2 (TXB 2 ) production in serum in the meloxicam group was extensive, but of shorter duration than the PGE 2 inhibition in exudate.